Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin - Drugs.com MedNews
Links shared publicly online about this topic.
- 788total visits
Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin - Drugs.com MedNews
Primary Endpoint Reduction in Bacterial Load - Met Positive Trends Observed in Time to First Exacerbation and Reduced Number of Exacerbations Statistically Sign
View full resource at drugs.com
Tags: Bronchiectasis, Drug, Antibiotic, Cipro, Ciprobay
Most Recently Shared on October 20, 2010 at 1:06 pm By:
Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin: Primary Endpoi... http://bit.ly/9rT6K7 #drug
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin
medicalnewstoday.com — “Aradigm Corporation (OTCBB:ARDM) (the Company) today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORB” View full resource at medicalnewstoday.com
Most Recently Shared on June 17, 2011 at 4:05 pm By:
MNT Cystic Fibrosis Health News
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin http://mnt.to/3Xmt #cysticfibrosis
Advertisement
